Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.
Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ.
Wenzl K, et al. Among authors: sarangi v.
Blood Cancer J. 2024 Jun 20;14(1):100. doi: 10.1038/s41408-024-01080-0.
Blood Cancer J. 2024.
PMID: 38902256
Free PMC article.